Integrating phytomedicine and nanotechnology in managing COVID-19 related heart disease

Acute coronary syndrome (ACS) in patients with SARS-CoV-2 infection represents a critical intersection of viral-induced inflammation and cardiovascular pathology. This review explores the dual mechanisms driving SARS-CoV-2-associated ACS and evaluates emerging therapeutic strategies, including phytomedicine and nanotechnology, to address both viral and cardiovascular complications.

SARS-CoV-2 and ACS pathogenesis

SARS-CoV-2 infection exacerbates ACS through systemic inflammation, endothelial dysfunction, and plaque destabilization. The virus triggers a cytokine storm, marked by elevated inflammatory biomarkers (e.g., IL-6, C-reactive protein), which promote platelet activation, thrombus formation, and coronary microvascular dysfunction. These processes are amplified by hypoxia and hemodynamic instability, creating a perfect storm for myocardial injury.

ACE2 receptor: A double-edged sword

The angiotensin-converting enzyme 2 (ACE2) receptor, essential for viral entry, is abundantly expressed in cardiovascular tissues. SARS-CoV-2 binding to ACE2 disrupts the renin-angiotensin system, exacerbating endothelial injury, vasoconstriction, and pro-thrombotic states. This receptor-mediated damage underlies both direct myocardial injury and indirect ischemic events, positioning ACE2 modulation as a therapeutic target.

Myocardial protective agents

While ACE inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) are debated due to their potential ACE2-upregulating effects, melatonin emerges as a promising adjunct. It enhances nitric oxide bioavailability, stabilizes plaques, and mitigates oxidative stress, offering cardioprotection during viral-induced inflammation.

Herbal medicine: Bridging antiviral and cardioprotective effects

Traditional Chinese medicine (TCM) demonstrates dual efficacy against SARS-CoV-2 and ACS:

• Licorice (Glycyrrhiza spp.): Glycyrrhizic acid inhibits viral replication via NF-κB and MAPK pathways while reducing oxidative damage through Nrf2 activation.

• Lianhua Qingwen granules: This formulation blocks ACE2-S protein binding, suppresses cytokine storms (IL-6, TNF-α), and improves endothelial function.

• Astragalus membranaceus and Honeysuckle: These herbs modulate immune responses, inhibit viral entry, and attenuate fibrosis, showcasing synergy in COVID-19 and cardiovascular management.

Non-herbal interventions

Peptide fusion inhibitors (e.g., EK1C4) and IL-1 antagonists (anakinra) show promise in reducing thromboembolic events and ACS incidence. Anakinra, in particular, improves survival in severe COVID-19 by curbing hyperinflammation, though its efficacy in advanced respiratory failure remains contentious.

Nanotechnology: Precision in therapy and prevention

Nanoparticle platforms revolutionize COVID-19 management:

• mRNA vaccines: Lipid nanoparticles in Pfizer-BioNTech and Moderna vaccines enhance mRNA stability and immunogenicity, achieving >95% efficacy.

• Nanoceria (NC): These antioxidant nanoparticles mitigate pulmonary fibrosis and acute respiratory distress syndrome (ARDS) via TGF-β inhibition.

• Silver nanoparticles (AgNPs): AgNPs disrupt viral replication and reduce cytokine storms, though toxicity and biodegradability challenges persist.
  Nanocarriers functionalized with ACE2-targeting ligands enable precise delivery of antiviral phytochemicals, enhancing therapeutic specificity.

Future directions

Key priorities include:

1. Clinical Trials: Large-scale studies to standardize TCM dosages and validate long-term safety.

2. Mechanistic Insights: Cryo-EM and molecular docking to elucidate herb-ACE2 interactions.

3. Nanotech Optimization: Improving nanoparticle targeting and clearance mechanisms.

4. Multi-Omics Integration: Identifying biomarkers for personalized phytotherapy.

Conclusion

SARS-CoV-2-associated ACS demands integrated strategies addressing viral pathogenesis and cardiovascular injury. Phytomedicine, exemplified by TCM, offers multi-targeted benefits, while nanotechnology enhances drug precision. Despite challenges in nanoparticle toxicity and herb standardization, these approaches herald a new era in managing COVID-19 complications. Bridging traditional wisdom with cutting-edge science could redefine therapeutic paradigms, emphasizing safety, efficacy, and holistic care in post-pandemic cardiology.